Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 11 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
977Linked to a medicine page here

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
  • Recommended: the NHS in England should fund it for the use it is licensed for.
  • Optimised: recommended, but for a narrower group of patients than the licence covers.
  • Cancer Drugs Fund / Innovative Medicines Fund: funded for a limited period while more evidence is collected.
  • Only in research: to be used only as part of a study.
  • Not recommended: NICE decided the NHS should not fund it for this use.
  • Terminated: the company did not send evidence, so NICE could not make a recommendation.

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Appraisals matching “Rituximab”

21 appraisals, newest first
AppraisalMedicine pageNICE recommendationPublishedStatus
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma
NICE TA1184
AcalabrutinibRecommended19 Aug 2026Current
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)
NICE TA703
IbrutinibTerminated (no company submission)26 May 2021Current
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA649
Polatuzumab VedotinRecommended23 Sep 2020Current
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
NICE TA629
ObinutuzumabRecommended13 May 2020Current
Lenalidomide with rituximab for previously treated follicular lymphoma
NICE TA627
LenalidomideRecommended7 Apr 2020Current
Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
NICE TA608
IbrutinibTerminated (no company submission)30 Oct 2019Current
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
NICE TA561
VenetoclaxRecommended27 Feb 2019Current
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
NICE TA472
ObinutuzumabRecommended (Cancer Drugs Fund)30 Aug 2017Replaced by TA629
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)
NICE TA437
IbrutinibTerminated (no company submission)22 Mar 2017Current
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
NICE TA308
RituximabOptimised26 Mar 2014Current
Rituximab for the first-line treatment of stage III-IV follicular lymphoma
NICE TA243
RituximabRecommended25 Jan 2012Current
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma
NICE TA226
RituximabRecommended22 Jun 2011Current
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)
NICE TA206
BendamustineTerminated (no company submission)27 Oct 2010Current
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
NICE TA195
Adalimumab, Etanercept, Infliximab, Rituximab, AbataceptOptimised Recommended25 Aug 2010Current
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
NICE TA193
RituximabOptimised Only in research28 Jul 2010Current
Rituximab for the first-line treatment of chronic lymphocytic leukaemia
NICE TA174
RituximabOptimised22 Jul 2009Current
Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma
NICE TA137
RituximabRecommended27 Feb 2008Current
Rituximab for the treatment of rheumatoid arthritis
NICE TA126
RituximabRecommended22 Aug 2007Current
Rituximab for the treatment of follicular lymphoma
NICE TA110
RituximabRecommended27 Sep 2006Replaced by TA243
Rituximab for aggressive non-Hodgkin's lymphoma
NICE TA65
RituximabRecommended Only in research24 Sep 2003Current
The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma
NICE TA37
RituximabOnly in research Not recommended27 Mar 2002Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 11 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.